Graefen M - Search Results

1

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.

Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: graefen m. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):139-148. doi: 10.1038/s41391-021-00395-4. Epub 2021 May 30. Prostate Cancer Prostatic Dis. 2022. PMID: 34054128 Free PMC article. Review.

2

Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma.

Henke RP, Hammerer P, Graefen M, Erbersdobler A, Neumann M, Berger J, Huland H. Henke RP, et al. Among authors: graefen m. Cancer. 1998 Sep 1;83(5):977-88. Cancer. 1998. PMID: 9731903

3

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.

Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H. Graefen M, et al. J Urol. 2002 Mar;167(3):1306-9. J Urol. 2002. PMID: 11832719

4

Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer.

Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, Kattan MW. Graefen M, et al. J Clin Oncol. 2002 Feb 15;20(4):951-6. doi: 10.1200/JCO.2002.20.4.951. J Clin Oncol. 2002. PMID: 11844816

5

Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?

Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham JA, Rabbani F, Fair W, Wheeler TM, Hammerer PG, Haese A, Erbersdobler A, Huland H, Scardino PT, Kattan MW. Cagiannos I, et al. Among authors: graefen m. J Clin Oncol. 2002 Apr 15;20(8):2025-30. doi: 10.1200/JCO.2002.08.123. J Clin Oncol. 2002. PMID: 11956261

6

Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.

Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H. Palisaar RJ, et al. Among authors: graefen m. Eur Urol. 2002 Feb;41(2):155-61. doi: 10.1016/s0302-2838(01)00025-2. Eur Urol. 2002. PMID: 12074402

7

International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.

Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. Graefen M, et al. J Clin Oncol. 2002 Aug 1;20(15):3206-12. doi: 10.1200/JCO.2002.12.019. J Clin Oncol. 2002. PMID: 12149292

8

A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men.

Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Huland H, Scardino PT, Kattan MW. Graefen M, et al. Urol Oncol. 2002 Jul-Aug;7(4):141-6. doi: 10.1016/s1078-1439(02)00177-1. Urol Oncol. 2002. PMID: 12474529

9

Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables.

Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Blonski J, Fernandez S, Erbersdobler A, Huland H. Graefen M, et al. Eur Urol. 2003 Jan;43(1):6-10; discussion 11. doi: 10.1016/s0302-2838(02)00497-9. Eur Urol. 2003. PMID: 12507538

10

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.

Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M, Scardino PT, Huland E, Huland H, Lilja H. Haese A, et al. Among authors: graefen m. Prostate. 2003 Feb 15;54(3):181-6. doi: 10.1002/pros.10180. Prostate. 2003. PMID: 12518322

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

923 results

Search Page